Download Free Medical Clinical Pharmacology Considerations During Phase 2 and Phase 3 of Drug Development PowerPoint Presentation

Clinical Pharmacology Considerations During Phase 2 and Phase 3 of Drug Development PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Clinical Pharmacology Considerations During Phase 2 and Phase 3 of Drug Development" by Su-Young Choi, Pharm.D., Ph.D.

This medical PowerPoint presentation is about phase 2 and phase 3 of drug development, duing which clinical pharmacology considerations play a crucial role in determining the safety and efficacy of the drug. Clinical pharmacology is the study of how drugs interact with the body and how the body responds to these interactions.

Tags : Clinical Pharmacology, Phase 2 of Drug Development, Phase 3 of Drug Development, pharmaceuticals, pharmaceuticals PowerPoint presentations

Published on : Jun 23, 2023 | Views : 1055 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Clinical Pharmacology 2: Clinical Pharmacology Considerations During Phase 2 and Phase 3 of Drug Development Su-Young Choi, Pharm.D., Ph.D Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences CDER, FDA The views expressed in this presentation are that of the author and do not reflect the official policy of the FDA. No official endorsement by the FDA is intended nor should be inferred.
Slide 2-

Objectives Understand the role of clinical pharmacology throughout drug development Understand the importance of analysis of exposure-response (E-R) relationship Describe the utility of E-R analysis throughout clinical development Understand barriers to informative E-R evaluation and key steps to the overcome the barriers Understand the impact of complete and incomplete clinical pharmacology programs on information available to health care providers
Slide 3-

Phases of Drug Development Phase 1 Investigate the safety, tolerability, and pharmacokinetics of the drug Allow selection of an appropriate dose range for Phase 2-3 Phase 2 Provide preliminary data on the safety and effectiveness of the drug Allow selection of appropriate doses for evaluation in Phase 3 Phase 3 Provide pivotal information about effectiveness and safety Allow evaluation of the overall benefit-risk relationship of the drug
Slide 4-

Examples of Phase 1-3 Trials Selected examples of dolutegravir Phase 1-3 trials Phase 1 trial Effects of low, moderate, or high fat meals on the pharmacokinetics of dolutegravir in 24 healthy volunteers Effects of dolutegravir on the pharmacokinetics of ethinylestradiol in 16 healthy female volunteers Phase 2 trial 278 HIV patients were randomly assigned to one of the following groups Dolutegravir 10 mg, 25 mg, 50 mg or standard of care (active control) Based on the safety and efficacy data collected in this trial, 50 mg was selected for the Phase 3 study Phase 3 trial 844 HIV patients were randomly assigned to dolutegravir 50 mg or standard of care (active control) Ann Pharmacother. 2015 Jul;49(7):784-9. Lancet Infect Dis. 2012 Feb;12(2):111-8. N Engl J Med 2013; 369:1807-1818 Antimicrob Agents Chemother. 2012 Mar; 56(3): 1627–1629.
Slide 5-

Pharmacokinetic Assessments during Phase 2-3 Trials While the primary goal of Phase 2-3 trials is to determine the safety and efficacy of a drug, blood (or target tissue) samples can be collected to determine the concentrations of the drug in Phase 2-3 trials Typically in a sparse manner in Phase 2-3 trials The sample collection schedule varies depending on PK characteristics, feasibility, and specific questions that you want to address. Example Dolutegravir Phase 3 trial Dosing regimen: 50 mg once daily for > 48 weeks Patients provided blood samples for pharmacokinetic analysis at the 4th, 24th, and 48th week of the treatment (at pre-dose or 1-3 hour post dose). Br J Clin Pharmacol. 2015 Sep;80(3):502-14.
Slide 6-

Clinical Pharmacology Evaluation during Phase 2-3 Trials Why do we collect drug concentration data during Phase 2-3 trials? i.e. what valuable information can we obtain, especially information that cannot be obtained from healthy volunteers “To link exposure (drug concentration) to safety and efficacy data”  Exposure-response relationship
Slide 7-

ppt slide no 7 content not found
Slide 8-

ppt slide no 8 content not found
Slide 9-

The Value of E-R Information Help design well-controlled studies (e.g., from Phase 2 to Phase 3) and select adequate doses for approval Does treatment effect/adverse event increase with dose/exposures? A dose may be selected for Phase 3 or approval even if it was not evaluated in previous trials. Contribute to substantial evidence of effectiveness Do data indicate a treatment effect? It may support approval when there are not two adequate and well controlled studies. ICH E4 dose-response information to support drug registration
Slide 10-

The Value of E-R Information Allow a better understanding of the clinical trial data What is the minimal effective concentration? What is the therapeutic window? Why do certain groups of people have lower efficacy or increased adverse events? Is it due to exposure differences? Adherence Patient factors (race/ethnicity, sex, hepatic/renal impairment) Concomitant medications
Slide 11-

The Value of E-R Information Support new target populations, use in subpopulations, new doses/dosing regimens, dosage forms and route of administration
Slide 12-

Example 1 – Dose selection for Phase 3 Dolutegravir --Integrase strand transfer inhibitor (INSTI) indicated for the treatment of HIV-1 infection Treatment-naive INSTI-resistance http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204790Orig1s000ClinPharmR.pdf
Slide 13-

Example 2 –Different Doses in Women Zolpidem: approved for the treatment of insomnia Zolpidem blood levels above 50 ng/mL  impairs driving to a degree that increases the risk of a motor vehicle accident Women appear to be more susceptible to this risk It is because they eliminate zolpidem from their bodies more slowly than men. After administering 10 mg zolpidem, about 15% of women and 3% of men had zolpidem concentrations that exceeded 50 ng/mL approximately 8 hours post-dosing. 15% women who take zolpidem at midnight may have impaired driving during their morning commute! http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm
Slide 14-

Example 2 –Different Doses in Women Current dosing recommendations for zoplidem (immediate release) The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm Higher exposure (concentration) in women  more adverse events (response) in women  lower doses used in women
Slide 15-

ppt slide no 15 content not found
Slide 16-

Example 4 – To Support the Approval of New Formulations and New Dosing Regimens A tablet formulation of drug X was evaluated in Phase 1-3 trials and approved. The current dosing regimen is 300 mg twice daily. After the approval, the company decided to develop a solution formulation for patients who cannot swallow tablets. After the approval, the company wanted to change the dosing regimen to 600 mg once daily to improve adherence.
Slide 17-

ppt slide no 17 content not found
Slide 18-

ppt slide no 18 content not found
Slide 19-

Barriers to Informative Exposure-Response Evaluation Data not collected or collected too late “…the general belief that the company conducted its pharmacokinetic/pharmacodynamic study too late in the game, leading to less than adequate dosing being brought forward in Phase III and for approval” – Pinksheet (9/16/2014) summarizing advisory committee meeting for parathyroid hormone Study design flaws Study conduct flaws lack of validated bioanalytical assay lack of documentation (dosing times not captured, sampling times not captured)
Slide 20-

Overcoming the BarrierGood Practice for Exposure-Response Evaluation Identification of key questions Details of some analyses can be defined beforehand. Design and interpretation based on pharmacology and physiological principles Example: tenofovir for the prevention of HIV transmission Adherence to the therapy is the key for the efficacy (prevention) Plasma concentration of tenofovir or emtricitabine: short half life Active metabolites in immune cells: longer half life  a better marker for the adherence Modified from CPT pharmacometrics Syst. Pharmacol (2015) 4, 565-575
Slide 21-

Good Practice for Exposure-Response Evaluation Good understanding of the assumptions and limitations Appropriate choice of analysis methods and datasets Various statistical models are available Which clinical trial results should be/should not be used? Appropriate handling of dropouts and covariates Modified from CPT pharmacometrics Syst. Pharmacol (2015) 4, 565-575
Slide 22-

Summary and Conclusion Without exposure-response information Dose selection may not be optimal We cannot interpret the significance of exposure changes Result: Lack of dosing instructions for certain groups They are deprived of therapy Or, they risk suboptimal safety and efficacy
Slide 23-

ppt slide no 23 content not found
Slide 24-

ppt slide no 24 content not found